Investor Presentaiton

Novo Nordisk Annual Report 2023 ESG initiatives Introducing Novo Nordisk Strategic Aspirations Risks Management Consolidated statements Additional information Reach Ambition Agenda Name Description E CO₂e emissions Purchasing renewable energy Range of solutions helping us move towards 100% renewable energy supply. This includes Renewable Electricity Certificates (REC), Power Purchase Agreements (PPA) and on-site renewable energy solutions. Global E Plastic S Access and affordability Minimising air transportation impact Three-fold approach to reduce CO₂e emissions associated to air transportation. This includes limiting business flights, reducing air freight of our products and purchasing Sustainable Aviation Fuel (SAF). Global Decarbonising supply chains Holistic effort to decarbonise our supply chain, with over 90% of CO₂e emissions coming from suppliers, by identifying and implementing levers within high-impact scope 3 categories. Global Set an absolute, near-term scope 3 reduction target by the end of 2024. Sustainable Markets Initiative (SMI) Public-private partnership, involving CEOS and leaders from healthcare organisations, that aims to decarbonise healthcare systems by reducing emissions from supply chains, patient care pathways and clinical trials. Global Converting to reusable devices Efforts to move away from single-use devices and convert into reusable devices that have a longer lifespan. While Novo Nordisk has manufactured reusable devices for almost 30 years, we intend to prioritise this conversion going forward. NWE¹, AU², CN³, CA4 Finding fossil-free plastic alternatives Recycling injection devices Efforts to find viable, lower-carbon alternatives to fossil-based plastic, which is present in the hundreds of millions of pens we produce every year. Take-back scheme tasked with recycling injection pens. This includes pilot programmes in a number of countries, and the world's first industry pilot in Denmark, in collaboration with Lilly, Sanofi and Merck. Access to Insulin Commitment Changing Diabetes® in Children Commitment to provide human insulin at a ceiling price of USD 3 per vial to governments and public tenders in 77 LMIC⁹, as well as USD 2 per vial to selected humanitarian organisations and NGOs. Public-private partnership providing comprehensive care for children and young people living with type 1 diabetes in LMIC. This includes free life-saving medicine and supplies for those up to 25 years old. Thermostable insulin iCARE Africa for Africa Partnering for Change Cross-functional initiative that challenges and re-evaluates the thermal stability of short- and intermediate-acting human insulin products. These are widely used in LMIC and humanitarian settings, where people with diabetes, and without access to stable cooling options, can benefit from revised storage guidance. Integrated business model, driven by our regional affiliate, that uses partnerships across sub-Saharan Africa to improve access to diabetes care. It does so by establishing and strengthening four building blocks of diabetes management: capacity, affordability, reach and empowerment. Global DK5, UK, BR7, FR LMIC 29 countries across AF10, ME¹¹, AS¹², SA13 LMIC Sub-Saharan Africa Commitment to significantly increase availability of insulin to people with diabetes on the African continent. It focuses on local production, and will both reduce the environmental footprint from transportation and support creation of local jobs. Africa Collaboration between the International Committee of the Red Cross (ICRC), the Danish Red Cross and Novo Nordisk investigating better approaches to care for people living with non-communicable diseases (NCDs) in humanitarian crises. We recognise the need to operate with proper regard to our impact on society and the environment. This table compiles some of our most significant initiatives within ESG. Achieve zero CO₂e emissions from operations by 2030. Achieve zero CO₂e emissions from transportation by 2030. Address 3.5 million tonnes of CO₂e per year across more than 100 of the members' largest pharmaceutical suppliers. Build on this year's conversions to raise the ambition level for 2024 and beyond. Replace plastic in our products with fossil-free alternatives. Collect 25% of the injection pens in Denmark within the industry pilot's first year, and achieve an 85% recycling rate by the end of 2024. Secure access to affordable insulin to significantly more people living with diabetes in LMIC. 2023 Progress Across Novo Nordisk, 63.2% of the energy sourced and 99.5% of the power sourced this year was renewable. At production sites, 61.3% of the energy sourced and 100% of the power sourced was renewable. We reduced CO₂e emissions associated to air transportation by 32%. We entered into the Sustainable Aviation Buyers Alliance (SABA) to purchase SAF, hereby securing significant investment and scalability in SAF solutions. We started an in-depth supplier engagement programme and roadmap development. This will continue throughout 2024. The SMI private sector CEOS launched joint, minimum environmental targets for suppliers. We increased our efforts to shift more patients towards reusable devices in Region North West Europe, Australia, China and Canada. We announced a partnership with the LEGO Group to buy e-methanol from European Energy and use it as a lower-carbon alternative to conventional plastics. Production of the resulting plastic is expected for 2025. We launched the world's first industry pilot in Denmark and are currently achieving a 50% recycling rate of the materials in the returned injection pens. An estimated 2.4 million people accessed care under this commitment. Reach 100,000 vulnerable children and young people living with type 1 diabetes by 2030. So far, we have reached 52,249 children and young people, trained 25,314 healthcare professionals and refurbished 406 clinics.. Reach national approvals in the 72 countries considered for revised storage conditions. Secure access to diabetes care for vulnerable patients. So far, we have 29 national approvals for more flexible storage conditions. We reached 433 thousand people with diabetes and trained 3,523 healthcare professionals. Produce more than 60 million vials by 2026. LB14, IQ15 Publish nine peer-reviewed articles on NCD care in humanitarian crises. We announced a partnership with South African-based pharmaceutical manufacturer Aspen Pharmacare to increase the production of insulin for the African continent. Six peer-reviewed articles were published, four are under review and an additional two are in the pipeline. 1. NWE: North West Europe. 2. AU: Australia. 3. CN: China. 4. CA: Canada. 5. DK: Denmark. 6. UK: United Kingdom. 7. BR: Brazil. 8. FR: France. 9. LMIC: Low- and middle-income countries. 10. AF: Africa. 11. ME: Middle East. 12. AS: Asia. 13. SA: South America. 14. LB: Lebanon. 15. IQ: Iraq. 102